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Aims The mechanistic basis of the symptoms and signs of myocardial ischaemia in patients without obstructive coronary
artery disease (CAD) and evidence of coronary microvascular dysfunction (CMD) is unclear. The aim of this study
was to mechanistically test short-term late sodium current inhibition (ranolazine) in such subjects on angina, myocardial
perfusion reserve index, and diastolic filling.
Materials
and results
Randomized, double-blind, placebo-controlled, crossover, mechanistic trial in subjects with evidence of CMD [invasive
coronary reactivity testing or non-invasive cardiac magnetic resonance imaging myocardial perfusion reserve index
(MPRI)]. Short-term oral ranolazine 500–1000 mg twice daily for 2 weeks vs. placebo. Angina measured by Seattle An-
gina Questionnaire (SAQ) and SAQ-7 (co-primaries), diary angina (secondary), stress MPRI, diastolic filling, quality of
life (QoL). Of 128 (96% women) subjects, no treatment differences in the outcomes were observed. Peak heart rate
was lower during pharmacological stress during ranolazine (23.55 b.p.m., P, 0.001). The change in SAQ-7 directly
correlated with the change in MPRI (correlation 0.25, P ¼ 0.005). The change in MPRI predicted the change in SAQ
QoL, adjusted for body mass index (BMI), prior myocardial infarction, and site (P ¼ 0.0032). Low coronary flow reserve
(CFR ,2.5) subjects improved MPRI (P, 0.0137), SAQ angina frequency (P ¼ 0.027), and SAQ-7 (P ¼ 0.041).
Conclusions In this mechanistic trial among symptomatic subjects, no obstructive CAD, short-term late sodium current inhibition
was not generally effective for SAQ angina. Angina and myocardial perfusion reserve changes were related, supporting
the notion that strategies to improve ischaemia should be tested in these subjects.
Trial registration clinicaltrials.gov Identifier: NCT01342029.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Coronary microvascular dysfunction † Angina
*Corresponding author. Tel: +1 310 423 9680; Fax: +1 310 423 9681; Email: noel.baireymerz@cshs.org
& The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits
non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
European Heart Journal (2016) 37, 1504–1513
doi:10.1093/eurheartj/ehv647
Introduction
Patients with symptoms, evidence of ischaemia, and no obstructive
coronary artery disease (CAD) are prevalent and increasing in
frequency.1 Such patients have disability, healthcare resource con-
sumption, and costs similar to those with obstructive CAD.2,3
Many have evidence for coronary microvascular dysfunction
(CMD), which is associated with adverse cardiovascular events.4 –7
Persistent symptoms are often atypical and a management challenge.
Thus, there are many gaps in our knowledge about these patients
related to their evaluation (invasive vs. non-invasive), mechanisms
responsible for their symptoms and CMD, and treatment targets.
Late sodium current inhibition with ranolazine is effective for
stable angina with obstructive CAD,8 – 15 and endorsed for such
patients in the most recent ESC guidelines.16 Ranolazine inhibits
the late sodium current in cardiomyocytes, decreasing Na+ and
Ca2+ overload. During ischaemia, excess intracellular Ca2+
impairs myocyte relaxation facilitating increases in ventricular
diastolic stiffness and further impaired perfusion. Ranolazine
also promotes the switch from the inefficient fatty acid metabol-
ism towards the oxygen-sparing glucose and lactate oxidation,
further reducing oxygen consumption. Evidence to date, how-
ever, has not clearly demonstrated whether the anti-anginal effect
is related to improved myocardial perfusion reserve. Further-
more, most CMD patients are women,17 yet pivotal trials with
ranolazine8 – 15 contained few women and studied effort angina
due to obstructive CAD.
Stress cardiac magnetic resonance perfusion imaging (CMRI) can
non-invasively detect CMD,18–20 and is associated with disordered
left ventricular (LV) diastolic function21 in CMD patients. A pilot trial
suggested benefit of ranolazine in CMD subjects with typical angina.22
Accordingly, we conducted a trial in subjects with symptoms with
no obstructive CAD, but evidence of CMD to mechanistically test
whether symptoms are related to myocardial perfusion reserve in-
dex and can be influenced by late sodium current inhibition (www.
clinicaltrials.gov, NCT01342029). The results should provide infor-
mation to address some of the aforementioned knowledge gaps and
direction for future studies in this enlarging population.
Methods
Patient population
Inclusion/exclusion criteria, study protocol, and list of investigators ap-
pear in Supplementary material online, Online Exhibit A. Briefly, we en-
rolled subjects with symptoms thought due to ischaemia, no obstructive
CAD (,50% epicardial coronary stenosis in all epicardial coronary ar-
teries), and preserved LV ejection fraction, who had abnormal coronary
reactivity testing (CRT) [coronary flow reserve (CFR) ,2.5, or no dila-
tion (≤0% change) with acetylcholine (Ach) response], or abnormal
stress CMRI ,2.0. Institutional Review Boards approved the study at
the two sites and subjects gave written informed consent.
Study design
To mechanistically test effects, we conducted a double-blind,
placebo-controlled, crossover trial, with short-term (2 week)
Figure 1 Study subject enrolment, screening, randomization and completion flow diagram. Treatment period 1 and 2: randomized to sequence
of ranolazine first followed by crossover to placebo, or vice-versa.
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ranolazine–placebo exposure order randomly assigned. Obstructive
CAD absence and CRT measures were verified [Women’s Ischemia
Syndrome Evaluation (WISE) Angiography and Coronary Reactivity
Cores]. At baseline, subjects completed demographic/health history
questionnaires, including the Seattle Angina Questionnaire (SAQ23
and SAQ-7),24 angina diary, Duke Activity Status Index (DASI),25 and
general quality of life (QoL).26 Anti-anginal medications were un-
changed. To maximize concurrent WISE recruitment, the study drug ex-
posure was reduced from the pilot study22 4–2 weeks followed by
2-week washout, and crossover to 2 weeks (see Supplementary mater-
ial online, Appendix and Figure 1). Ranolazine (Gilead Sciences, Foster
City, CA, USA) was administered as 500 mg orally twice daily for
1-week and increased to 1000 mg twice daily for 1-week as tolerated
(subjects taking verapamil or diltiazem maintained 500 mg b.i.d. of rano-
lazine or placebo). Treatment compliance was measured by pill count.
Data were collected at baseline (SAQ) and at the end of each treatment
period (SAQ, CMRI).
The angina and nitroglycerin diary,12 SF-36,26 MOS-116,27 and
HIS-GWB Mental Health Battery28 were used as previously described.29
Cardiac magnetic resonance imaging
The CMRI protocol (see Supplementary material online, Exhibit B) was
performed (1.5 Tesla magnet, Siemens Sonata, Erlangen, Germany) with
ECG-gating and phased array coil with 0.05 mmol/kg gadolinium
first-pass perfusion three slice at rest, during pharmacological
and cold-pressor stress.30 Myocardial scar was determined by late
gadolinium enhancement (LGE) in a subset. Adenosine (140 mg/kg/min)
or regadenoson (0.4 mg) if intolerant was consistent for periods.
Cardiac magnetic resonance imaging was conducted under identical
conditions and timing, dosing, and settings, 4-h after the morning
study drug dose.
First-pass perfusion images were analysed using CAAS MRV CMRI
analysis software Version 3.3 (Pie Medical Imaging B.V., Maastricht,
the Netherlands). Software determined epicardial and endocardial
contours of LV myocardium were manually corrected for MPRI inten-
sity–time curves. Global sub-endocardial and sub-epicardial MPRI were
calculated as the ratio of stress/rest relative perfusion upslope, corrected
for LV cavity upslope (higher is better myocardial perfusion reserve). The
sub-endocardial and sub-epicardial layers were software determined as
the inner and outer 50% wall thickness. These methods have high inter-
study and observer reproducibility,31,32 with best reproducibility in the
mid-ventricle.18 An MPRI ≤1.8 is considered abnormal,20 and correlates
with CRT20 and risk factors.33 Left ventricular mass and volumes were
evaluated by manual tracing; papillary muscles were included in the LV
mass/excluded from the LV volume. Volumetric diastolic filling was
used to calculate early peak filling rate (PFR) and time to PFR (tPFR).21
Invasive coronary reactivity testing
Clinically indicated invasive CRT measured coronary micro- and macro-
vascular endothelial and non-endothelial-dependent function6,34 was
available in 87 subjects (62.5%). Coronary flow reserve was measured
by Doppler flow-wire (FloWirew Volcano, San Diego, CA, USA) follow-
ing intracoronary (IC) adenosine injections, while graded IC Ach
assessed endothelial function.
All measurements were made in the WISE Angiographic, CMRI, and
CRT Core Labs masked to treatment period.
Statistical analysis
Subjects were randomized at a 1:1 ratio and blocked by clinical site.35
Using a 2 × 2 crossover design, a sample size of 116 would achieve
90% power to detect a mean difference of 15 in SAQ score22 using a
two-sided t-test at the 0.017 Holm–Bonferroni-corrected level of sig-
nificance (HB), and standard deviation of 43.4 for paired difference in
SAQ angina stability scores.22 Given the smaller standard deviations
of the difference for the other two co-primary endpoints, the current
trial was well powered for all the co-primary endpoints. A 10% attrition
was assumed and target sample size was 134.
The analytic approach was a within-subjects comparison (paired) of
the difference between baseline-treatment periods (SAQ, QoL) (a total
of four measurements per subject, including two baselines and two
treatment periods) or treatment periods (CMRI) (a total of two mea-
surements per subject, including two treatment periods). The distribu-
tion of within-subjects differences was assessed to deploy appropriate
statistical techniques. The primary approach was a standard paired
t-test. Linear regression models were tested using treatment differences
as the outcome. A stepwise procedure was used to choose the variables
that were significantly associated with the outcomes. The overall type I
error rate for the three co-primary outcome measures was controlled
at 5% by the HB36 sequential procedure. Carry-over effects tested the
interaction between treatment and period by comparing the mean with-
in subject with means between the arms.37 Sub-group analyses included
relevant clinical variables,15 prior ranolazine exposure, randomization
sequence, site, adenosine vs. regadenoson, full vs. reduced ranolazine
dose, prior myocardial infarction by history or CMRI-LGE, and qualifying
CRT and CMRI variables. The significance level for outcomes other than
the three co-primary endpoints was set to 0.05. A subject was included
if they completed SAQ at baseline, SAQ, and CMRI for both treatment
periods, and ≥50% of drug for both periods. Analyses were performed
using SAS v9.3 (SAS Institute, Inc., Cary, NC, USA).
Study oversight
The study was investigator-initiated as an ancillary trial to the NHLBI-
sponsored WISE, funded in part by Gilead Sciences, and used the
WISE Data Safety Monitoring Committee. Statistical analysis was
performed by the investigators independent of NHLBI and Gilead.
The decision to submit for publication was made by the principal
investigators who had access to all data after the last subject
completed the study.
Results
Subject characteristics
Between 12 May 2011 and 10 August 2015, 435 subjects were
screened, 393 eligible, 153 (96% women) enrolled, 10 (7%) subjects
failed CMRI screening and 1 dropped out before randomization
(Table 1 and Figure 1). Among the 142 randomized, 8 (6%) dropped
out (1 before receiving treatment, 5 while receiving ranolazine, 1
during placebo washout, and 1 while receiving placebo), and an add-
itional 3 (2%) missed one or both treatment periods. This yielded
128 subjects with data from both periods available for analysis.
Many subjects were receiving beta-blockers, angiotensin-
converting enzyme inhibitors, and statins. Despite anti-anginal ther-
apy, all subjects had symptoms thought by their physicians to
represent ischaemia although only 31% had typical angina. Among
the 98 subjects with WISE baseline CMRI, 11% had myocardial
scar by LGE (7-sub-endocardial or transmural, 3-mid-myocardial
or epicardial or mixed, and 1-indeterminate), 69% had MPRI
≤1.8. Among the 87 subjects with baseline CRT, 38% had a CFR
of ,2.5. Systolic and diastolic blood pressures were 123+ 18
and 72+12 mmHg, respectively.
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Compliance and safety
Overall compliance was 97%, while 21% (ranolazine) and 14%
(placebo) subjects reduced to the 500 mg twice daily dosing for
side-effects. Serious adverse events during the ranolazine period
occurred in five patients [hospitalization for NSTEMI (1); broncho-
spasm (1); chest pain, dizziness, and pre-syncope (2); and syncope
(1)], during the washout periods were hospitalization for chest
pain (ranolazine washout, 1 patient) and bradycardia (placebo wash-
out, 1 patient), and 0 during the placebo. Non-serious adverse
events during ranolazine occurred in seven subjects—nausea and
dizziness (3), arm shaking (1), back pain (1), renal abnormality (1),
and throat swelling (1); in six subjects during placebo—chest pain
(3), throat swelling (1), cough (1), and sinus infection (1); and in
two subjects during washout—chest pain (1) and rectocele (1).
Angina, QoL, haemodynamics, and
CMRI results
None of the primary outcomes, other SAQ subscales, or angina or
nitroglycerin use diary improved during ranolazine vs.. placebo
(Table 2). Due to a higher variance in the baseline-treatment com-
parison, we also directly compared treatment periods14 and ob-
served improved SAQ angina stability (7.23+ 37.54, P ¼ 0.03)
and SAQ-7 (1.94+ 12.90, P ¼ 0.09) (neither significant at the
0.017 level). QoL depression improved during ranolazine (P ¼
0.0091) (Table 2). Results did not differ by menopausal status, or
by excluding men. Mixed modelling in the entire cohort with treat-
ment data demonstrated similar results.
Overall, CMRI was interpretable in 127 pharmacological and
126 cold-pressor stress tests. We observed significantly lower
pharmacological stress mean heart rate (HR) and rate-pressure
product (RPP) during ranolazine vs. placebo (Table 2), but other-
wise no haemodynamic differences. Pharmacological stress MPRI
did not significantly improve with ranolozine vs. placebo (Table 2),
nor did cold pressor (data not shown), or HR-corrected pharma-
cological stress MPRI (mid-ventricular global 2.06+ 0.53 vs. 2.0+
0.42, P ¼ 0.15) or mid-ventricular sub-endocardial (1.83+ 0.48
vs. 1.77+ 0.38, P ¼ 0.18). Because myocardial flow reserve can
be confounded by resting flow due to dependency on myocardial
workload, we further corrected the resting MPRI with RPP and
found similar results. Diastolic filling rates were similar for PFR
with a trend towards higher tPFR (P ¼ 0.09) on ranolazine vs. pla-
cebo (Table 2).
The change in SAQ-7 directly correlated with the change in MPRI
(correlation 0.25, P ¼ 0.005). In a multiple linear regression analysis,
the MPRI-midventricular change differed by site and prior MI, ad-
justed for body mass index (BMI), and SAQ QoL change (P ¼
0.008). All of the angina variables were tried in the model. Two
SAQ variables could enter into the models singly, but not at the
same time: SAQ QoL and SAQ-7. Each of these had similar associa-
tions with the MPRI variables, but QoL has slightly better model fit
statistics. The treatment difference in the QoL-depressed question
had a significant positive association when added to the model
for global mid-ventricular MPRI (P ¼ 0.024), but was not significant
for sub-endo or sub-epi mid-ventricular MPRI (P ¼ 0.058 and P ¼
0.075, respectively). Modelling result demonstrated that as the
estimated MPRI mid-ventricular change increased, SAQ QoL change
increased, adjusted for BMI, prior MI and site (P ¼ 0.004) (Figure 2A).
Similar results were observed with mid-ventricular sub-endocardial
MPRI (P ¼ 0.003) (Figure 2B).
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Table 1 Baseline demographic and clinical variables
Variables Mean+ SD,
or absolute
frequency (%)
Age (years) 55.2+9.8
Female 96%
BMI 29.3+7.6
.30 50 (39.7%)
Race (non-Caucasian) 31 (24.2%)
Tobacco use
Current 2 (1.6%)
Former 38 (29.7%)
Never 88 (68.8%)
History of hypertension 69 (53.9%)
History of diabetes 23 (18.0%)
History of hyperlipidaemia 70 (54.7%)
Family history of premature coronary artery disease 83 (64.8%)
Post-menopausal (n ¼ 123) 100 (81.3%)
Symptoms
Typical Angina 40 (31.3%)
Shortness of Breath 88 (68.8%)
Palpitations 53 (41.4%)
Nausea 40 (31.3%)
Angina frequency (baseline SAQ angina frequency
domain)
59.6+26.9
LV Ejection Fraction (%) 67.8+7.7
Qualifying CMRI (n ¼ 86)a
Global myocardial perfusion reserve index
(MPRI) ,2 (n ¼ 67)b
1.6+0.3
Qualifying CRT (n ¼ 87)a
LV end-diastolic filling pressure (LVEDP)
(mmHg) (n ¼ 74)
14.8+5.1
Qualifying CFR ,2.5 (n ¼ 35)b 2.2+0.2
Qualifying Ach response ,0%b (n ¼ 36) 20.6+15.6
Beta-blockers 54 (42.2%)
Calcium current blockers; non-dihydropyridine 29 (22.7%);
7 (24%)
Angiotensin-converting enzyme inhibitors 27 (21.1%)
Angiotensin receptor vlockers 13 (10.2%)
Nitrates 50 (39.1%)
Statins 74 (57.8%)
Hormone replacement therapy 16 (12.5%)
Ach, acetylcholine; BSA, body surface area; BMI, body mass index; CFR, coronary
flow reserve; CMRI, cardiac magnetic resonance imaging; CRT, coronary reactivity
testing; MPRI, myocardial perfusion reserve index; LV, left ventricular; SAQ, Seattle
Angina Questionnaire.
aSubjects could have both CRT and CMRI.
bSubjects could have CMRI and CFR and Ach qualifiers.
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Sub-group CRT analysis of the subjects using a clinically significant
threshold of CFR ,2.534 had higher global (ANOVA, P ¼ 0.038)
and mid-ventricular MPRI improvement during ranolazine
compared with CFR 2.5–3 and above 3 (ANOVA, P ¼ 0.014,
Figure 3). Among subjects with CFR ,2.5, the treatment difference
for SAQ angina frequency and SAQ-7 change was higher during
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Table 2 Seattle Angina Questionnaire (SAQ), angina diary, functional capacity and quality of life (QoL), haemodynamic,
myocardial perfusion reserve and diastolic filling treatment effect
Ranolazine Placebo Treatment changea
Mean SD N Mean SD N Mean 95% CI N P-value
SAQ
Physical limitation 68.09 23.34 123 66.70 23.34 120 20.22 (23.23, 2.79) 114 0.89
Angina stabilityb 58.40 26.11 128 51.17 27.68 128 5.12 (23.51, 13.75) 127 0.24
Angina frequency b 63.91 26.09 128 62.73 25.95 128 0.08 (24.18, 4.34) 128 0.97
Treatment satisfaction 74.16 21.23 127 74.17 21.08 128 20.48 (23.98, 3.03) 127 0.79
QoL 56.05 23.09 128 54.17 23.31 128 0.91 (22.44, 4.27) 128 0.59
SAQ overall 62.49 19.32 128 60.97 20.11 128
SAQ-7
Physical limitation 71.67 24.18 124 70.15 25.03 122
Angina frequency 63.91 26.09 128 62.73 25.95 128
QoL 55.76 27.97 128 52.83 28.59 128
SAQ-7 overallb 63.54 21.09 128 61.60 22.32 128 1.31 (21.56, 4.17) 128 0.37
Angina diary
Angina episode 4.78 8.20 128 4.88 7.75 128 20.10 (20.94, 0.73) 128 0.81
NTG usage 2.48 10.16 128 2.62 11.18 128 20.13 (21.0, 0.74) 128 0.76
SF-36
Energy/fatigue 47.49 20.93 128 46.45 20.43 128 1.40 (22.27, 5.07) 119 0.45
Emotional 70.12 17.14 128 68.28 16.97 128 2.82 (20.56, 6.19) 119 0.10
MOS-116
Moody 5.09 1.05 127 4.92 1.19 128 0.14 (20.12, 0.41) 118 0.28
Low spirits 5.12 1.08 127 5.05 1.13 128 0.10 (20.12, 0.32) 118 0.36
HIS-GWB
Depressed 4.39 0.74 127 4.27 0.87 128 0.20 (0.05, 0.36) 118 0.009
Strain 4.28 1.41 127 4.20 1.44 128 0.11 (20.20, 0.42) 118 0.49
DASI score 6.35 4.83 128 6.20 5.05 128 0.31 (20.58, 1.21) 128 0.49
Pharmacological stress
HR (b.p.m.) 95.17 13.50 128 98.73 14.15 128 23.55 (24.99, 22.12) 128 <0.001
SBP (mmHg) 127.2 21.60 129 127.3 20.9 128 20.56 (23.93, 3.10) 129 0.75
DBP (mmHg) 60.17 16.52 129 60.32 16.57 128 20.49 (23.23, 2.52) 129 0.73
Stress RPP 12 082 2707 128 12 611 2796 128 2523 (2901, 297) 128 0.010
Global MPRI 1.98 0.46 128 1.96 0.42 125 0.01 (20.08, 0.09) 125 0.88
MPRI mid–sub-endocardial 1.83 0.48 127 1.77 0.38 124 0.06 (20.04, 0.15) 124 0.23
Diastolic filling
PFR (mL/s) 333.3 105.9 127 328.8 97.1 128 4.3 (29.05, 17.71) 127 0.52
tPFR (ms) 163.9 45.3 127 157.4 37.7 128 6.6 (21.13, 14.33) 127 0.09
DASI, Duke Activity Status Index [in metabolic equivalents (METS)]; HIS-GWB Mental Health Battery; HR, heart rate; MOS 116, Medical Outcomes Study; MPRI, myocardial
perfusion reserve index; MPRI-mid, mid-ventricular MPRI; mL, milliliter; NTG, nitroglycerin; PFR, peak filling rate; Pharmacologic Stress, adenosine or regadenoson infusion; QoL,
quality of life; RPP, rate-pressure product; SAQ, Seattle Angina Questionnaire; ms, milliseconds; SF-36, MOS-36-Item Short-Form Health Survey; tPFR, time to peak filling rate.
aThe SAQ, QoL, and DASI were measured pre- and post-treatment for both periods. All other outcomes were measured only post-treatment. Treatment change for SAQ, QoL,
and DASI are the difference ranolazine-placebo in post- to pre-treatment changes.
bThe HB critical levels were used for testing the three co-primary endpoints.
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ranolazine than placebo (paired t-test 9.43+24.13, P ¼ 0.027 and
6.62+ 18.46, 0.041, respectively). Sub-group analysis according
to typical vs. non-typical angina was negative; however, subjects
with prior MI (n ¼ 10) had higher global (0.30, P ¼ 0.047) and
sub-epicardial MPRI (0.32, P ¼ 0.027) during ranolazine vs. placebo.
Discussion
In this short-term mechanistic trial, an anti-anginal agent effective for
effort angina in patients with obstructive CAD, late Na current
blockade with ranolazine, did not generally improve symptoms,
Figure 2 Mid-ventricular and mid-ventricular sub-endocardial myocardial perfusion reserve index change vs. Seattle Angina Questionnaire qual-
ity of life change (ranolazine vs. placebo) model. The observed change in mid-ventricular myocardial perfusion reserve index (A) and mid-
ventricular sub-endocardial myocardial perfusion reserve index (B) are plotted against the observed differences in treatment change for Seattle
Angina Questionnaire quality of life with a line depicting a simple linear regression. The Pearson correlation and standard error (r, SEE) for this
association are shown with the P-value for the test against zero correlation. The multiple regression described in the results showed that as myo-
cardial perfusion reserve index–mid-ventricular change increased, Seattle Angina Questionnaire quality of life change increased, adjusted for body
mass index, prior myocardial infarction and site (P ¼ 0.005) with a similar model results for myocardial perfusion reserve index–
mid-sub-endocardial change and Seattle Angina Questionnaire quality of life change (P ¼ 0.005). Other variables tested that were not selected
by the model include: pharmacological stress heart rate change, age, body mass index, site, history of hypertension, history of diabetes, prior
ranolazine use, gender, left ventricular mass, end-diastolic volume, quality of life depressed change, had menopausal symptoms, baseline Seattle
Angina Questionnaire angina frequency, Seattle Angina Questionnaire change (each of the five subdomains), adenosine vs. regadenson, and
ranolazine dose level.
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myocardial perfusion reserve index, or diastolic filling in symptom-
atic subjects with no obstructive CAD but evidence of CMD. These
findings suggest that short-term late sodium current inhibition with
ranolazine is not generally effective for symptoms in this novel popu-
lation. However, changes in angina and myocardial perfusion reserve
index were directly related, indicating that symptoms are related to
ischaemia in this population, supporting the case that therapies with
the potential to improve ischaemia should be tested. Myocardial
perfusion reserve index improved in sub-group of subjects with
lower baseline CFR, consistent with prior study findings.42,43
Invasively determined CRT is perhaps a more rigorous determin-
ation of CFR and comparable with PET.20,38,39 Among the entire co-
hort, slightly more than half underwent a clinically indicated invasive
CRT, and 38% had low CFR ,2.5. Our result suggests that late
sodium current inhibition with ranolazine may beneficially improve
angina and myocardial perfusion reserve index in such a rigorously
defined CMD population with more severe CMD. This result sug-
gests that subjects with more severe CMD may benefit and should
be included in future trials testing strategies to improve ischaemic
morbidity and mortality.
Interestingly, stress HR and RPP on ranolazine was 4 b.p.m.
lower vs. peak stress HR during placebo. Stress HR is an important
determinant of myocardial oxygen demand, while pharmacological
stress predominantly alters myocardial oxygen supply via arteriolar
dilation (both coronary and systemic), the HR increase is mediated
by reflex increases in beta-adrenegic activity. Furthermore, we ob-
served a lower RPP during pharmacological stress on ranolazine vs.
placebo supporting the suggestion that myocardial oxygen demand
was lower during stress on ranolazine. To our knowledge, this is
the first description of such an effect of ranolazine in humans.
The pharmacological basis for our finding is suggested from experi-
mental studies which have shown attenuated ranolazine dose-
dependent isoproterenol increases in HR (beta1 receptor) and
decreases in blood pressure (beta2 receptor) in rat and conscious
dog models40,41 and also supported by beta-adrenergic receptor
binding data.41 The results indicate that ranolazine has a weak effect
to antagonize beta-adrenergic receptors during stress. A minority of
our subjects were on beta-blockers or non-dihydropyridine calcium
current blockers, although these and the other anti-anginal medica-
tions were withdrawn for the stress testing. This HR effect also con-
tributed to a small reduction in RPP supporting the suggestion that
myocardial oxygen demand during stress was somewhat lower at
the same MPRI. We may have observed different myocardial perfu-
sion reserve and symptom responses if had we used exercise testing,
as in previous ranolazine trials.8 –14
Our current results differ from the pilot study22 used to design
this CMD mechanistic trial. The current subjects had a much lower
prevalence of typical or ‘effort angina’ (31 vs. 95%, respectively),
which may explain the lack of anti-anginal benefit measured by the
SAQ in the current results. Current subjects were also more obese
(BMI 29.3+ 7.5 vs. 25.6+ 3.8, respectively), which may have
impacted drug distribution and effect. While baseline SAQ scores
were comparable, our pre-specified analysis plan compared baseline-
treatment SAQ scores (a more conservative measure), vs. direct
comparison of treatment periods in prior studies.22,42 Qualifying
myocardial perfusion reserve was higher (better) in the current
cohort vs. our pilot (overall CMRI MPRI 1.8+0.5 vs. 1.40+0.43,
respectively). While we did not have pilot measures of diastolic filling,
LV end-diastolic pressure in CRT was comparable in the current and
pilot (14.8+5.1 vs. 14.71+5 mmHg, respectively).
Our current results are also not consistent with two recent, but
smaller studies in subjects with no obstructive CAD and CFR as-
sessed by transthoracic Doppler. One studied 58 patients (only
19 women), with angina and abnormal myocardial perfusion, in a
double-blind, placebo-controlled parallel trial of ranolazine
500 mg twice daily or placebo for 8-weeks. Ranolazine increased
CFR and most SAQ domains vs. placebo.42 Another studied 46 pa-
tients with effort angina, abnormal exercise tests, CFR ,2.5 and
persistent symptoms on anti-anginal agents, randomized to rano-
lazine (n ¼ 15: 12 women, 375 mg twice daily), ivabradine or pla-
cebo (n ¼ 15: 12 women) for 4-weeks. Ranolazine improved the
SAQ vs. placebo and achieved better results vs. ivabradine: exer-
cise time to 1-mm ST-segment depression and duration.43 More
men, more typical effort angina, use of exercise testing, direct
treatment period SAQ comparison, use of directly-measured
CFR, and more severe CMD likely contributed to these different
results.
Women comprised 96% of our population, precluding conclu-
sions regarding response in men. Pivotal chronic angina trials with
ranolazine were comprised mostly of men (75%).8 – 10 One was
designed to determine dose–response and efficacy and found
improvement in exercise time with doses used in the current trial,
without suggestion of differential effects among men vs. women.8
Another found that ranolazine had similar angina and nitroglycerine
use in women as in men, although less improvement on exercise
testing-related angina.9 Importantly, subjects in these prior ranola-
zine trials had effort angina due to obstructive CAD.
Figure 3 Myocardial perfusion reserve index change according
to qualifying coronary flow reserve in the subset of subjects with
invasive coronary reactivity testing. Among subjects with qualifying
coronary reactivity testing available coronary flow reserve and
both period myocardial perfusion reserve index (n ¼ 78), lower
coronary flow reserve had significantly greater mid-ventricular
myocardial perfusion reserve index change on ranolazine vs. pla-
cebo (P ¼ 0.014). A higher myocardial perfusion reserve index
number indicates better myocardial perfusion reserve.
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Study limitations
Although the largest study to date in subjects with no obstructive
CAD but CMD, our study by design was a mechanistic trial. Its
strengths include a rigorous crossover design, use of validated
measures and core laboratories, and CMRI and CRT evaluation.
Limitations include a short-term 2-week exposure to ranolazine,
although exposure duration was the same as a prior trial.10 Also,
by design, only a subset qualified by clinically ordered CRT, and
these subjects may have had lower CFR than those who qualified
by CMRI, raising the possibility that more severe CMD explained
the beneficial ranolazine response observed in this sub-group. The
CFR analysis suggesting this concept is a sub-group, and therefore
underpowered with a wide standard deviation, although significant
and consistent with prior CFR studies. Use of angina diaries for an-
gina is often limited by inappropriate input of multiple entries in a
single sitting (so-called hoarding) and low compliance (as low as
11%).44 While we used objectively assessed MPRI, a validated quan-
titative myocardial perfusion reserve method, MPRI is based on the
relative upslopes of arrival of myocardial contrast at stress and rest,
which correlates with, but is not a direct measure of, CFR. Our fu-
ture CMRI work will use our newly developed radial imaging and ab-
solute CFR computation.45 The use of diastolic filling as a measure
of diastolic function is a limitation as new approaches including tissue
tagging acquisition,21 and post-processing diastolic function soft-
ware46 appear to be improved measures; prior work has shown
that ranolazine improves LV diastolic function.47,48 The SAQ, used
and validated among predominantly elderly men from a Veterans
Administration hospital with effort angina due to obstructive
CAD, may not measure the atypical ‘angina-equivalents’ such as
shortness of breath, fatigue, indigestion, and weakness in this pre-
dominantly female population. Indeed, other symptoms may have
completely different causes, including dyspnoea can be explained
by obesity and palpitations are a frequent component of the post-
menopausal syndrome. Furthermore, we modified the SAQ to a
2-week period to fit the protocol. Finally, we used selected SF-36,
MOS-166, and HIS-GWB QoL variables, which may be less reliable
than the full measures; however, the practice of using selected gen-
eral QoL measures as part of lengthy batteries of questionnaires as-
sessing disease-specific QoL is common.29
Conclusions
In this mechanistic trial, short-term late Na current blockade (rano-
lazine) effective for effort angina in patients with obstructive CAD
did not significantly improve symptoms or myocardial perfusion re-
serve index in subjects with no obstructive CAD but evidence of
CMD. This suggests that short-term late sodium current inhibition
is not generally effective for SAQ angina in this novel population.
Changes in the SAQ and myocardial perfusion reserve index were
directly related, indicating that symptoms are related to myocardial
perfusion reserve, supporting the notion that strategies to improve
ischaemia should be tested in these subjects.
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